Both of these games were road games for Florida

Do any particular teams seem to have Coach Meyer's number While no one particular team seems to have an upper hand on the current Florida Gators coaching staff, six of the eight losses came by the hands of SEC West schools.Digging a little deeper into Meyer's record, of the eight SEC losses, only three occurred in The Swamp. When the Gators lost to an SEC West team, four of the six losses came on the road.2005 was Meyer's first season in Gainesville and while the team dropped three SEC contests, two of the losses were to SEC West teams Alabama trounced the Gators 31-3 while LSU won 21-17. Both of these games were road games for Florida.Florida finished the 2006 regular season 11-1, and only Auburn prevented the Gators from finishing with their first ever undefeated season, losing 27-17.2007 brought the Gators three losses, all in the SEC. A rare home loss in The Swamp (to Auburn, 20-17), a loss to Georgia in Jacksonville, and yet another road loss at LSU (28-24).Ole Miss, a 22 point road dog, ended Florida's hopes of an undefeated season in 2008. The Rebels walked out of Ben Hill Griffin Stadium with a 31-30 win.Four seasons, eight SEC losses.

Outside of the loss to the Crimson Tide in 2005, Meyer's average margin of loss is a low 4.75 points.A complete rundown of the losses to SEC West teams:2005: at Alabama (UF favored by 3), lost 31-3at LSU (UF was a 6 point road dog), lost 21-172006: at Auburn (UF was favored by 2), lost 27-172007: vs Auburn (UF was favored by 17), lost 20-17at LSU (UF was a 7 point road dog), lost 28-242008: vs Ole Miss (UF was favored by 22), lost 31-30Coming into this weekend's game against the Arkansas Razorbacks, the Gators are favored by 22 points. Will the Razorbacks be this year's SEC West road loss for FloridaFlorida is riding high as the number one team in the country. MONTGOMERYVILLE, Pa.(Business Wire)PhotoMedex, Inc. (Nasdaq:PHMD) announced the results of its 2009 AnnualStockholders Meeting held on January 26, 2009, at the offices of Morgan, Lewis& Bockius LLP, 1701 Market Street, Philadelphia, PA 19103. The following matters were approved by the Companys stockholders: Election to the Companys Board of Directors each of Richard J DePiano,Jeffrey F ODonnell, Alan R Novak, Anthony J Dimun, David W Anderson, WayneM Withrow and Stephen P Connelly.

Ratification of the appointment of Amper, Politziner & Mattia, LLP as theCompanys independent registered public accounting firm for the fiscal yearending December 31, 2008. An amendment to the Companys 2005 Equity Compensation Plan to increase thenumber of shares of the Companys common stock, reserved for issuance thereunderfrom 6,160,000 to 8,160,000 shares and add provisions relating to the grant ofperformance-based stock awards that are designed to qualify as "qualifiedperformance-based compensation" under Internal Revenue Code Section 162(m). Issuance of shares of the Companys common stock pursuant to the terms andconditions of the Securities Purchase Agreement, dated as of August 4, 2008, byand between the Company and Perseus Partners VII, L.P., and upon conversion ofthe Promissory Notes and exercise of the Warrants, each as issued pursuant tothe Securities Purchase Agreement. An amendment to the Companys Certificate of Incorporation to effect a reversestock split of the Companys outstanding common stock at an exchange ratio of1-for-7 and authorize the Companys Board of Directors to implement the reversestock split at any time prior to the 2010 annual meeting of stockholders byfiling an amendment to the Companys Certificate of Incorporation. An amendment to the Companys Certificate of Incorporation to increase thenumber of authorized shares of common stock from 100,000,000 shares to150,000,000.Following the Stockholder Meeting, on January 26, 2009, the Company filed anamendment to its Certificate of Incorporation to effect the reverse stock splitand the increase in the number of authorized shares of common stock. About PhotoMedexPhotoMedex is engaged in the development of proprietary excimer laser and fiberoptic systems and techniques directed toward dermatological applications, withFDA 510(k) clearances to market the XTRAC laser system for the treatment ofpsoriasis, vitiligo, atopic dermatitis and The Company is a leader in thedevelopment, manufacturing and marketing of medical laser products and services.In addition, as a result of the merger with ProCyte, PhotoMedex now develops andmarkets products based on its patented, clinically proven Copper Peptidetechnology for skin health, hair care and wound care.